SYNDAX PHARMACEUTICALS INC (SNDX)
Health Care · Clinical-stage biopharmaceutical oncology and fibrotic disease therapies · NASDAQ
Syndax is a commercial-stage biopharmaceutical company with two FDA-approved oncology drugs (REVUFORJ and NIKTIMVO) partnered with major pharma, generating rapid revenue growth from product sales and collaborations.
What SYNDAX PHARMACEUTICALS INC does
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company that develops and commercializes therapies for cancer and fibrotic diseases. The company has two FDA-approved marketed products: REVUFORJ (revumenib), an oral selective menin inhibitor, and NIKTIMVO (axatilimab-csfr), which it co-develops and commercializes through a collaboration with Incyte Corporation. Syndax operates through licenses with major pharmaceutical partners including UCB Biopharma and AbbVie (through Vitae Pharmaceuticals), and generates revenue from product sales and collaboration arrangements.
Themes: ["oncology / cancer therapeutics","menin inhibitors","fibrotic diseases","partnered drug development"]
Fundamentals
- Price$24.84 as of 2026-07-09 close
- Market cap$2.2B as of 2026-07-10
- 1-year return+168.8% as of 2026-07-09 close
- Net margin-111.9% as of 2026-07-10
- Gross margin+96.0% as of 2026-07-10
- ROE-256.7% as of 2026-07-10
- Debt / equity8.26 as of 2026-07-10
- Revenue growth (YoY)+397.3% as of 2026-07-10
- Beta0.35 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on collaboration revenue and milestone payments from Incyte and other licensors; ability to maintain licenses with UCB and Vitae/AbbVie is critical to continued operations","Clinical efficacy and safety of product candidates may not be replicated in future trials; regulatory approval timing and likelihood remain uncertain","Market adoption of REVUFORJ and NIKTIMVO by physicians and patients is not assured; failure to achieve commercial traction would severely impact revenues"]
Competitors & peers
- Incyte Corporation (INCY)
- AbbVie (ABBV)
- UCB (Union Chimique Belge)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.